Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease after study entry and before tisagenlecleucel infusion. Here,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Bishop, Michael R., Maziarz, Richard T., Waller, Edmund K., Jäger, Ulrich, Westin, Jason R., McGuirk, Joseph P., Fleury, Isabelle, Holte, Harald, Borchmann, Peter, del Corral, Christopher, Tiwari, Ranjan, Anak, Özlem, Awasthi, Rakesh, Pacaud, Lida, Romanov, Vadim V., Schuster, Stephen J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2019
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650727/
https://ncbi.nlm.nih.gov/pubmed/31332046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000151
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares